Tommie Perusich
Psychiatric/Mental Health · Butte, MTNPI 1194364091
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Neuronetics, Inc. accounts for 72.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $2,855 and has fallen 90.1% since, to $282 in 2025. Among psychiatric/mental health clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $99.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$421
- Neurocrine Biosciences, Inc.$152
- Johnson & Johnson$130
- Janssen Scientific Affairs, LLC$115
- AbbVie$65
- plus $188 from 7 others
What the payments were for
- Consulting fees$1153%
- Travel & lodging$2,30560%
- Food & beverage$1,39536%
- Education$471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 3 | $2,792 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $421 |
| Neurocrine Biosciences, Inc. | 7 | $152 |
| Johnson & Johnson | 3 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| AbbVie | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Amgen | 1 | $36 |
| Novo Nordisk | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$2,755
- SPRAVATO$115
- CAPLYTA$114
How this compares
$3,862 in reported general payments places this provider in the 95th percentile of 142 psychiatric/mental health providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 22 | $61,634 |
| VraylarCariprazine Hcl | 18 | $25,137 |
| Paliperidone ErPaliperidone | 34 | $7,604 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 133 | $3,875 |
| Clozapine | 25 | $2,373 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $1,833 |
| Aripiprazole | 63 | $1,703 |
| Bupropion XlBupropion Hcl | 93 | $1,477 |
| Duloxetine Hcl | 44 | $983 |
| Gabapentin | 80 | $849 |
| Naltrexone Hcl | 18 | $733 |
| Quetiapine Fumarate | 79 | $682 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $615 |
| Lurasidone Hcl | 22 | $586 |
| Fluoxetine Hcl | 94 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $130 | $61,63422 claims |
| AbbVieVraylar | $65 | $25,13718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 psychiatric/mental health providers in Montana.
Other psychiatric/mental health in Butte
- Elizabeth HollingsworthButte$1K
- Danielle BertramButte$1K
- Kindra ParksButte$1K
- Peggy WolsteinButte$770
- Sherrie EavesButte$581
- Krista BrysonButte$448
- Robin BeckerButte$353
- Tayler RydalchButte$341
- Amber DayhuffButte$292
- Heather BrownKalispell$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.